Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

por Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P J
Publicado 2014

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

por Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., Landewé, R.
Publicado 2015

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD st...

por Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V
Publicado 2008

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Ph...

por Landewé, R, Braun, J, Deodhar, A, Dougados, M, Maksymowych, W P, Mease, P J, Reveille, J D, Rudwaleit, M, van der Heijde, D, Stach, C, Hoepken, B, Fichtner, A, Coteur, G, de Longueville, M, Sieper, J
Publicado 2014